

Sabinsa successfully protects its Curcumin C3 Reduct technology

Sabinsa Corporation announced today that it has successfully concluded its Patent Infringement lawsuit against Olive Lifesciences Pvt. Ltd.

ETHealthWorld | May 05, 2018, 15:34 IST



Sabinsa Corporation announced today that it has successfully concluded its Patent Infringement lawsuit against Olive Lifesciences Pvt. Ltd. On April 5, 2018, the United States District Court in New Jersey entered an judgment awarding Sabinsa over \$850,000 in damages, enhanced damages, attorney's fees, costs, and interest.

On June 8, 2016, Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr. Muhammed Majeed. The '327 Patent protects Sabinsa's novel methods and formulations for tetrahydrocurcuminoids (THCs).

The judgment concludes that the '327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa

has successfully litigated willful infringement of the '327 patent and has obtained judgments against other infringers.

Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr. Majeed stated. "As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry," said Dr. Majeed. "The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property," he continued.

"We are very proud of our long-term partnership with Sabinsa to make sure that its intellectual property is enforced and respected in the industry," added James H. Hulme, Sabinsa's counsel. "Sabinsa can now point to a string of patent victories after this latest judgment," Mr. Hulme said.



Sami-Sabinsa wins patent infringement lawsuit against Olive Lifesciences

The lawsuit battle between Sabinsa Group and Bengaluru based Olive Life Sciences has been over former's patented technology, Curcumin C3 Complex in a colourless, non-staining form

By BioVoice Correspondent - April 24, 2018



New Delhi: Sami-Sabinsa Group has announced that it has successfully concluded its Patent Infringement lawsuit against Bangalore based Olive Lifesciences on April 5, 2018. As per the company, the United States District Court in New Jersey entered a judgment awarding Sabinsa over \$850,000 in damages, enhanced damages, attorney's fees, costs, and interest.

On June 8, 2016, Sami-Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr Muhammed Majeed. The '327 Patent protects Sabinsa's novel methods and formulations for tetra-hydro-curcuminoids (THCs).

Curcumin C3 Reduct is a Registered Trademark and Patented product of Sami-Sabinsa and is protected under U.S. Patent No. 6,653,327, and International Patents. This ingredient provides many of the benefits of Sabinsa's Curcumin C3 Complex in a colourless, non-staining form.

The judgment concludes that the '327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sami-Sabinsa has successfully litigated willful infringement of the '327 patent and has obtained judgments against other infringers.

Sami-Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr Majeed stated. "As a pioneer in the industry, Sami-Sabinsa has researched and developed many innovative products used by the nutritional supplement industry," Dr Majeed added "The success has spawned many imitators, and Sami-Sabinsa will not hesitate to enforce its patents and other intellectual property," he continued.

"We are very proud of our long-term partnership with Sami-Sabinsa to make sure that its intellectual property is enforced and respected in the industry," added James H. Hulme, Sabinsa's counsel. "Sami-Sabinsa can now point to a string of patent victories after this latest judgment," Mr Hulme said.

As per Sami-Sabinsa, it has pioneered the introduction of several herbal extracts in the U.S. market as an application-oriented manufacturing and marketing company which manufactures herbal extracts and speciality fine chemicals used for nutritional, pharmaceutical, cosmeceutical, and food products.



Sami-Sabinsa protects its Curcumin C3 Reduct Technology



Sami-Sabinsa Group recently announced that it has successfully concluded its Patent Infringement lawsuit against Bangalore based Olive Lifesciences Pvt. Ltd. on April 5, 2018, the United States District Court in New Jersey entered an judgment awarding Sabinsa over \$850,000 in damages, enhanced damages, attorney's fees, costs, and interest.

On June 8, 2016, Sami-Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr. Muhammed Majeed. The '327 Patent protects Sabinsa's novel methods and formulations for tetrahydrocurcuminoids (THCs).

The judgment concludes that the '327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sami-Sabinsa has successfully litigated willful infringement of the '327 patent and has obtained judgments against other infringers.

Sami-Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr. Majeed stated. "As a pioneer in the industry, Sami-Sabinsa has researched and developed many innovative products used by the nutritional supplement industry," said Dr. Muhammed Majeed, Founder, Sami-Sabinsa Group. "The success has spawned many imitators, and Sami-Sabinsa will not hesitate to enforce its patents and other intellectual property," he continued.

"We are very proud of our long-term partnership with Sami-Sabinsa to make sure that its intellectual property is enforced and respected in the industry," added James H. Hulme, Sabinsa's counsel. "Sami-Sabinsa can now point to a string of patent victories after this latest judgment," Mr. Hulme said.

Sami-Sabinsa, which has pioneered the introduction of several herbal extracts in the U.S. market, is an application-oriented manufacturing and marketing company which manufactures herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical, cosmeceutical, and food products. The group distinguishes itself with its extensive research support for its customers and products, and the scientific credentials of its key technical staff.

Curcumin C3 Reduct® is a Registered Trademark and Patented product of Sami-Sabinsa, and is protected under U.S. Patent No. 6,653,327, and International Patents. This ingredient provides many of the benefits of Sabinsa's Curcumin C3 Complex® in a colorless, non-staining form.

Nutritional OUTLOOK

Sabinsa Wins Latest Curcumin Patent Infringement Lawsuit



By Jennifer Grebow. Apr 24, 2018

Curcumin-ingredients supplier Sabinsa Corp. (East Windsor, NJ) has prevailed in its latest patent-infringement lawsuit, this time against Olive Lifesciences Pvt. Ltd., a botanical extract supplier based in India. Sabinsa announced that in April, the United States District Court in New Jersey awarded the company \$850,000 in damages, ruling that Olive Lifesciences infringed on Sabinsa's patent covering novel methods and formulations for producing tetrahydrocurcuminoids.

Tetrahydrocurcuminoids are metabolites of the curcuminoids found in turmeric (*Curcuma longa*). Sabinsa's researchers have long contended that these tetrahydrocurcuminoids are superior to curcuminoids, providing more active and effective benefits, including stronger physiological effects and better absorption. Since 2003, Sabinsa has held a U.S. patent (#6,653,327) covering compositional claims as well as several topical and oral applications of tetrahydrocurcuminoids. Sabinsa markets its trademarked and colorless tetrahydrocurcuminoid Curcumin C3 Reduct ingredient under the umbrella of this patent. Sabinsa also retains tetrahydrocurcuminoids patents in Europe, Australia, and New Zealand.

The New Jersey District Court judge ruled that Olive Lifesciences willfully infringed on Sabinsa's patent. The company has vigorously defended its tetrahydrocurcuminoids patent. In July 2017, it won consent judgment against a company called Aegle Bios Inc., over the same patent, and has obtained final judgments against two other companies, Chemill Inc. and Nachurel Ingredients, as well. In 2016, Sabinsa announced that it had entered into a licensing agreement with Chemill.

In a press release announcing the firm's latest victory, Sabinsa's founder, Muhammed Majeed, PhD, stated, "As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry. The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property."

"Sabinsa can now point to a string of patent victories after this latest judgment," said James H.



Sabinsa awarded \$850,000 in curcuminoids patent suit

By Hank Schultz. 24-Apr-2018 - Last updated on 24-Apr-2018 at 15:58 GMT



Sabinsa Corporation has prevailed in a patent infringement lawsuit against an Indian competitor based on the intellectual property supporting its Curcumin C3 Reduct technology.

Sabinsa, which is based in Bangalore, India with other bases of operations in India as well as in New Jersey and Utah, supplies a variety of botanical extracts and fine chemicals. The company has been a leader in the development of curcuminoid ingredients. It sources its raw material for these and other botanicals from a bevy of small holder farmers in India and elsewhere.

Success breeds imitators

The burgeoning popularity of curcuminoid ingredients has brought many competitors into the market, some of whom are not playing by the rules as far as Sabinsa is concerned. After a lengthy patent dispute with competitor Olive Lifesciences Pvt. Ltd. the United States District Court in New Jersey entered a judgment on April 5 awarding Sabinsa more than \$850,000 in damages, enhanced damages, attorney's fees, costs, and interest.

The company had first filed the suit on June 8, 2016. It covers Sabinsa's US Patent No. 6,653,327 covering Sabinsa's novel methods and formulations for tetrahydrocurcuminoids (THCs).

According to Sabinsa, the judgment concludes that the '327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa has successfully litigated willful infringement of the '327 patent and has obtained judgments against other infringers.

"As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry," said Sabinsa's founder Dr. Muhammed Majeed. "The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property."

Olive Lifesciences did not respond in time for publication to a request for comment.

WholeFoods

MAGAZINE

Informing and Educating the Natural Products Industry

Sabinsa Successfully Protects its Curcumin C3 Reduct Technology



By **WholeFoods Magazine Staff** - April 24, 2018

Piscataway, NJ – Sabinsa Corporation has successfully ended its patent infringement lawsuit against Olive Lifesciences Pvt. Ltd.

On April 5, the United States District Court in New Jersey entered a judgment awarding Sabinsa over \$850,000 in damages, enhanced damages, attorney's fees, costs, and interest, according to a statement from the company.

On June 8, 2016, Sabinsa filed suit against Olive for willful infringement of U.S. Patent No. 6,653,327, according to Sabinsa founder Dr. Muhammed Majeed. The '327 Patent protects Sabinsa's novel methods and formulations for tetrahydrocurcuminoids (THCs).

The judgment concludes that the '327 Patent is valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa has successfully litigated willful infringement of the '327 patent and has obtained judgments against other infringers.

Sabinsa has a well-earned reputation for strong enforcement of its intellectual property rights and will continue to pursue all available legal remedies to protect those rights, Dr. Majeed stated. "As a pioneer in the industry, Sabinsa has researched and developed many innovative products used by the nutritional supplement industry," said Dr. Majeed. "The success has spawned many imitators, and Sabinsa will not hesitate to enforce its patents and other intellectual property," he added.